[A long-term response to eribulin]

Bull Cancer. 2018 Jul-Aug;105(7-8):636-638. doi: 10.1016/j.bulcan.2018.05.002. Epub 2018 Jun 14.
[Article in French]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Breast Carcinoma In Situ / diagnostic imaging
  • Breast Carcinoma In Situ / drug therapy*
  • Breast Carcinoma In Situ / secondary
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Capecitabine / administration & dosage
  • Carcinoma, Ductal, Breast / diagnostic imaging
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / secondary
  • Female
  • Fluorouracil / administration & dosage
  • Furans / therapeutic use*
  • Humans
  • Ketones / therapeutic use*
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Middle Aged
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Antineoplastic Agents
  • Furans
  • Ketones
  • Bevacizumab
  • Vinblastine
  • Capecitabine
  • eribulin
  • Vinorelbine
  • Fluorouracil